Brinzolamide NEW
| Price | $30 | $58 | $89 |
| Package | 10mg | 25mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2025-05-21 |
Product Details
| Product Name: Brinzolamide | CAS No.: 138890-62-7 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2025/05/21 |
Product Introduction
Bioactivity
| Name | Brinzolamide |
| Description | Brinzolamide (AL-4862) is a Carbonic Anhydrase Inhibitor. Its mechanism of action involves inhibiting the enzyme Carbonic Anhydrase. |
| In vitro | A 0.6 mg dose of Brinzolamide ophthalmic suspension reduces intraocular pressure in a dose-dependent manner in cynomolgus monkeys post-laser glaucoma surgery. Similarly, it lowers intraocular pressure in Dutch belted rabbits. Dosages of 1 mg/kg, 10 mg/kg, and 30 mg/kg of Brinzolamide prolong the sleep time induced by barbital in male CD-1 mice by 57%, 15%, and 35%, respectively. Less than 3% of Brinzolamide significantly increases both the percentage reduction and the mean decrease in intraocular pressure among patients with primary open-angle glaucoma or ocular hypertension compared to a placebo group. Additionally, a 2% Brinzolamide solution enhances optic nerve head blood flow and reduces intraocular pressure in resting Dutch belted rabbits. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 60 mg/mL (156.45 mM), Sonication is recommended. |
| Keywords | IOP | intraocular pressure | Inhibitor | inhibit | glaucoma | CarbonicAnhydrase | carbonic anhydrase II | Carbonic anhydrase II | Carbonic Anhydrase | Carbonate dehydratase | Brinzolamide | atrial fluid | AL4862 | AL 4862 |
| Inhibitors Related | Benzenesulfonamide | Urea | Cyclamic acid sodium | Hydrochlorothiazide | Orthanilamide | Tioxolone | Zonisamide | Histone acetyltransferase p300 Inhibitor 4c | EMAC10101d | pNNP | Levosimendan | Trichlormethiazide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Glycometabolism Compound Library | Bioactive Compound Library | Approved Drug Library | EMA Approved Drug Library | Anti-Cancer Metabolism Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Metabolism Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 | ||
| $1.00 |
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-26 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-18 | ||
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-06-12 | ||
| $30.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | |
| $30.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
|
VIP4Y
|
shandong perfect biotechnology co.ltd
|
2026-03-27 | ||
|
VIP4Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2026-01-04 | ||
| $50.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 | ||
| $30.00 |
Shandong Xuhuang New material CoLTD
|
2025-03-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY